• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Boehringer Ingelheim (Group)

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development. *

 

	Start	1885-01-01 established
	Industry	pharmaceutical
	Person	Boehringer, Christian (Boehringer 201207 Chairman of Shareholders’ Committee)
	Person 2	Barner, Andreas (Boehringer)
	Region	Ingelheim
	Country	Germany
	Street	173 Binger Str.
	City	55216 Ingelheim
	Tel	+49-6132-770
		Address record changed: 2018-07-24
Basic data	Currency	EUR
	Annual sales	15,850,000,000 (sales, net, consolidated (2016) 2016-12-31)
	Profit	1,849,000,000 (2016-12-31)
	Cash	6,603,000,000 (2016-12-31)
		* Document for �About Section�:
		Record changed: 2019-06-23

Advertisement

More documents for Boehringer Ingelheim (Group)

• [1] Boehringer Ingelheim. (6/11/19). "Press Release: The Healthcare of Tomorrow – Boehringer Ingelheim Relies on Digital Transformation". Ingelheim....
• [2] Amal Therapeutics S.A.. (5/2/19). "Press Release: Amal Therapeutics Enters Clinical Collaboration with Boehringer Ingelheim to Evaluate ATP128 in Combination with BI754091". Geneva....
• [3] PureTech Health plc. (4/17/19). "Press Release: PureTech Health Announces Collaboration with Boehringer Ingelheim to Advance Immuno-oncology Product Candidates Using Its Lymphatic Targeting Platform". Boston, MA....
• [4] Boehringer Ingelheim. (3/7/19). "Press Release: Novel Antibody Shows Potential to Transform Treatment of Rare Form of Psoriasis". Ingelheim....
• [5] Boehringer Ingelheim. (2/25/19). "Press Release: New Chief Medical Officer Appointed". Ingelheim....
• [6] Boehringer Ingelheim (Canada) Ltd.. (2/12/19). "Press Release: Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials". Burlington, ON & Markham, ON....
• [7] Boehringer Ingelheim. (1/24/19). "Press Release: Boehringer Ingelheim Partners with AMPATH to Scale Up Knowledge, Skills and Training for Healthcare Providers in Kenya". Ingelheim....
• [8] Autifony Therapeutics Ltd.. (1/18/19). "Press Release: Autifony Therapeutics Achieves First Milestone in Agreement with Boehringer Ingelheim for a Novel Therapeutic Approach to a Range of CNS Disorders". Stevenage....
• [9] Boehringer Ingelheim. (1/17/19). "Press Release: Boehringer Ingelheim Biopharmaceuticals China Expands Commercial Manufacturing Capacities". Shanghai....
• [10] BioMed X GmbH. (1/17/19). "Press Release: BioMed X and Boehringer Ingelheim to Investigate Early Intervention in Psychiatric Diseases". Heidelberg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.